is a five-year project of the Innovative Medicines Initiative (IMI), a EU public-private consortium consisting of patient networks, learned societies, SMEs, pharmaceutical companies and academia. BigData@Heart's ultimate goal is to develop a Big Data-driven translational research platform of unparalleled scale and phenotypic resolution in order to deliver clinically relevant disease phenotypes, scalable insights from real-world evidence and insights driving drug development and personalised medicine through advanced analytics.
NIHR Health Informatics Collaborative
The Health Informatics Collaborative
brings together five of the country's leading NIHR Biomedical Research Centres to make NHS clinical data more readily available to researchers, industry and the NHS community. Working in collaboration with UCLH, our lab contributes to the development of scalable data integration pipelines
for critical care electronic health recods data.
The UK Biobank
is a large prospective biobanked cohort of 500,000 middled-aged adults with extensive genomic, baseline and electronic health record data participants. Our lab is leading the efforts of
creating and validating acute coronary syndrome phenotypes and undertaking a series of phenome-wide association studies (PheWAS) by exploiting the rich clinical information found in health records.
The Intellectual Disability and Mental Htalth: Assessing Genomic Impact on Neurodevelopment
(IMAGINE ID) study seeks to increase our understadning of children and young people with intellectual disability that has a genetic cause. Our lab is leading the health informatics workstream of the study with the aim of creating a legacy database integrating genomic, clinical and baseline data for research.
A team of researchers from UCL and the University of Cambridge led by Prof. Sarah Tabrizi, Director of the Huntington's Disease Centre, UCL Institute of Neurology, have been granted a prestigious Wellcome Trust Collaborative Award in one of the largest investments in Huntington's Disease ever given by a public funding body in the UK.
The 5-year, 3.4 million pound investment will support TREAT HD
to help our understanding of disease mechanisms in HD and, importantly, their response to treatment.
is an international collaboration to investigate the genetic architecture of heart failure. The consortium comprises 42 population-based studies and clinical trials across Europe and North America and includes over 30,000 heart failure cases and over 200,000 controls. The Consortium's aim is to generate insights into the causal pathways leading to heart failure to inform new therapeutic approaches.